A Biomarker Screening Protocol for Participants With Solid Tumors (START)

Lyell Immunopharma

Status: Terminated

Conditions: Relapsed Cancer; NSCLC Stage IV; NSCLC, Recurrent; High Grade Serous Carcinoma; Ovarian Epithelial Cancer; Fallopian Tube Cancer; Non Small Cell Lung Cancer; Ovarian Cancer; Non-Small Cell Carcinoma of Lung, TNM Stage 4; Platinum-resistant Ovarian Cancer; Endometrial Cancer; Recurrent NSCLC; Non Small Cell Lung Cancer Metastatic; Advanced Lung Carcinoma; Primary Peritoneal Carcinoma; Non-small Cell Lung Cancer; Endometrioid Tumor; Triple Negative Breast Cancer; Recurrent Breast Cancer; Relapse/Recurrence; NSCLC; Advanced Breast Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT05891197

LYLSCR-101

Details and patient eligibility

About

Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissue will be allowed on this study for biomarker analysis. Fresh tumor biopsies are not permitted on this study. The study will be conducted virtually and participants will utilize telehealth and e-consent modules. If participants tumors express the biomarkers of interest they can be referred to open and enrolling clinical trials. Participation on the screening study does not guarantee enrollment or treatment on an interventional clinical trial.

Enrollment: 10 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Participants aged ≥ 18 years at time of informed consent
2. Able to provide informed consent
3. Histologically or cytologically confirmed diagnosis of advanced or metastatic solid tumor malignancy.The Sponsor will indicate which solid tumor disease indications are open to enrollment.
4. Ability to provide a tumor tissue sample collected within 3 years prior to enrollment. The sample must consist, at minimum, of 5 freshly cut, unstained 4-5 μM sections cut from a formalin-fixed paraffin-embedded (FFPE) tissue block. The sample must contain sufficient tumor tissue to allow for the evaluation of biomarker expression

Exclusion criteria

1. Prior solid organ transplantation
2. Prior treatment with any adoptive cell therapy
3. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with a clinical study, as judged by the Investigator or Sponsor's Medical Monitor